目次

1. Need For Breast Cancer Immunotherapy?
1.1 Overview
1.2 Breast Cancer Immunotherapy Mechanism Of Action
1.3 Potential Breast Cancer Biomarkers

2. Global Breast Cancer Immunotherapy Market Overview
2.1 Breast Cancer Global Market Insight: Yearly and Quarterly Sales (2019 - 2023)
2.2 Global Breast Cancer Immunotherapy Market Future Outlook (2023 - 2028)

3. Global Breast Cancer Immunotherapy Trend Analysis
3.1 US
3.2 UK
3.3 Canada
3.4 Europe
3.4.1 Germany
3.4.2 France
3.4.3 Italy
3.4.4 Spain
3.4.5 Poland
3.4.6 Belgium
3.5 Australia
3.6 China
3.7 Japan
3.8 South Korea
3.9 India

4. Global Breast Cancer Immunotherapy Approved Drugs Sales, Price, Dosage and Patent Analysis
4.1 Keytruda (Pembrolizumab)
4.2 Perjeta (Pertuzumab)
4.3 Kadcyla (Ado-Trastuzumab Emtansine)
4.4 Phesgo (pertuzumab trastuzumab hyaluronidase)
4.5 Trodelvy (Sacituzumab Govitecan)
4.6 Herceptin (Trastuzumab)
4.7 Enhertu (Fam-Trastuzumab Deruxtecan)
4.8 Margenza (Margetuximab)
4.9 Tecentriq (Atezolizumab)
4.10 Avastin (Bevacizumab)

5. Global Breast Cancer Immunotherapies Clinical Trials Insight
5.1 By Biomarker
5.2 By Company
5.3 By Country
5.4 By Patient Segment
5.5 By Phase

6. Global Breast Cancer Immunotherapies Clinical Trials By Company, Country and Indication
6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-II/III
6.7 Phase-III
6.8 Preregistration
6.9 Registered

7. Marketed Breast Cancer Immunotherapies Clinical Insight

8. Therapeutic Approaches To Breast Cancer Immunotherapy
8.1 Monotherapeutic Approaches
8.2 Combination Therapy Approach
8.2.1 Combination Of Targeted Therapy and Endocrine Therapy
8.2.2 Combination With Immunotherapy
8.2.3 Combination Strategies That Include Triple Agents

9. New Immunotherapeutic Approaches In Trials For Breast Cancer Treatment
9.1 Emerging Molecular Targets For CAR T Cell Immunotherapy
9.2 Bispecific Antibodies
9.3 Vaccine Based Therapy
9.4 Oncolytic Viruses
9.5 Immunotherapy with Tumor Infiltrating Lymphocytes (TILs)
9.6 Cytokine Therapy

10. Global Breast Cancer Immunotherapy Market Dynamics
10.1 Market Drivers
10.2 Market Challenges

11. Competitive Landscape
11.1 Roche
11.2 Genentech
11.3 Amgen
11.4 Antibody Therapeutics
11.5 Pfizer
11.6 Merck
11.7 Novartis
11.8 Bristol-Myers Squibb
11.9 EirGenix
11.10 Prestige BioPharma
11.11 Novartis Oncology
11.12 Protheragen
11.13 Merck
11.14 LeadArtis
11.15 Mayo Clinic
11.16 Biocad
11.17 Therabest Korea
11.18 EpiThany
11.19 AstraZeneca
11.20 PACT Pharma
11.21 Xuanzhu Biopharmaceutical
11.22 Samsung Bioepis
11.23 Shanghai Novamab Biopharmaceuticals
11.24 ImmunityBio

List of Figures & Tables
Figure 1-1: Conventional Treatment Strategies Used for Breast Cancer
Figure 1-2: Classification of Immunotherapy
Figure 1-3: Different Immunotherapeutic Approaches
Figure 1-4: Majorly used current biomarkers for Breast Cancer
Figure 1-5: Emerging and Novel Biomarkers for Breast Cancer
Figure 2-1: Global - Breast Cancer immunotherapy Market Sales (US$ Billion), 2019 - 2023
Figure 2-2: Global - Breast Cancer immunotherapy Market Quarterly Sales (US$ Billion)’ 2022
Figure 2-3: Global - Breast Cancer immunotherapy Market By Drug (US$ Million), Q1’2023
Figure 2-4: Global - Breast Cancer immunotherapy Market By Drug (US$ Million), 2022
Figure 2-5: US - Breast Cancer immunotherapy Market (US$ Billion)’ 2019 - 2023
Figure 2-6: US - Breast Cancer immunotherapy Market By Drug (US$ Million), Q1’2023
Figure 2-7: US - Breast Cancer immunotherapy Market By Drug (US$ Million), 2022
Figure 2-8: Europe - Breast Cancer immunotherapy Market (US$ Million)’ 2019 - 2023
Figure 2-9: Europe - Breast Cancer immunotherapy Market By Drug (US$ Million), Q1’2023
Figure 2-10: Europe - Breast Cancer immunotherapy Market By Drug (US$ Million), 2022
Figure 2-11: Global - Breast Cancer immunotherapy Market Sales (US$ Billion), 2023 - 2028
Figure 3-1: US - Share of Breast Cancer Cases In Total Cancer Cases, 2022
Figure 3-2: US - Reimbursement System
Figure 3-3: UK - Share of Breast Cancer Cases In Total Cancer Cases, 2020
Figure 3-4: UK - Key Reimbursement Stakeholders
Figure 3-5: Canada - Share of Breast Cancer Cases In Total Cancer Cases, 2020
Figure 3-6: Canada - Drug Reimbursement Process
Figure 3-7: Europe - Share of Breast Cancer Cases In Total Cancer Cases, 2020
Figure 3-8: Germany - Reimbursement Of Drugs
Figure 3-9: France - Drug Pricing and Reimbursement Process
Figure 3-10: Italy - Drug Pricing and Reimbursement Process
Figure 3-11: Spain - Pricing and Reimbursement Process
Figure 3-12: Poland - Stages Of Reimbursement Decision Making Process
Figure 3-13: Australia - Drug Payment Process
Figure 3-14: China - Share of Breast Cancer Cases In Total Cancer Cases, 2020
Figure 3-15: China - Negotiation Process for National Reimbursement Drug List (NRLD)
Figure 3-16: Japan - Share of Breast Cancer Cases In Total Cancer Cases, 2020
Figure 3-17: Japan - Reimbursement Process For Public Insured Medical Services
Figure 3-18: South Korea - Share of Breast Cancer Cases In Total Cancer Cases, 2020
Figure 3-19: South Korea - Flow Of Reimbursement Decision making For New Drug
Figure 4-1: Global - Keytruda Annual Sales (US$ Million), 2019 - 2023
Figure 4-2: Global - Keytruda Quarterly Sales (US$ Million), 2022
Figure 4-3: US - Keytruda Annual Sales (US$ Million), 2019 - 2023
Figure 4-4: US - Keytruda Quarterly Sales (US$ Million), 2022
Figure 4-5: US - Keytruda Price per Unit and per Vial for 25mg/mL Intravenous Solution (US$), May’2023
Figure 4-6: Keytruda - List Price of a Supply for 3 and 6 Weeks (US$), May’2023
Figure 4-7: Keytruda - Cost of Treatment for Different Administration Schedules, May’2023
Figure 4-8: UK - Keytruda Price per 100mg/4mL Intravenous Solution, May’2023
Figure 4-9: Keytruda - Patent Expiration Year
Figure 4-10: Global - Perjeta Annual Sales (US$ Million), 2019 - 2023
Figure 4-11: Global - Perjeta Quarterly Sales (US$ Million), 2022
Figure 4-12: US - Perjeta Annual Sales (US$ Million), 2019 - 2023
Figure 4-13: US - Perjeta Quarterly Sales (US$ Million), 2022
Figure 4-14: Europe - Perjeta Annual Sales (US$ Million), 2019 - 2023
Figure 4-15: Europe - Perjeta Quarterly Sales (US$ Million), 2022
Figure 4-16: Japan - Perjeta Annual Sales (US$ Million), 2019 - 2023
Figure 4-17: Japan - Perjeta Quarterly Sales (US$ Million), 2022
Figure 4-18: US - Perjeta per Unit and Price for 420mg/14mL Intravenous Solution (US$), May’2023
Figure 4-19: Perjeta - Total Cost Of Treatment Cycle (US$), May’2023
Figure 4-20: UK - Perjeta Price per Vial of 420mg/14mL, May’2023
Figure 4-21: Perjeta - Patent Filing Year v/s Expiration Year - US, Canada and Australia
Figure 4-22: Global - Kadcyla Annual Sales (US$ Million), 2019 - 2023
Figure 4-23: Global - Kadcyla Quarterly Sales (US$ Million), 2022
Figure 4-24: US - Kadcyla Annual Sales (US$ Million), 2019 - 2023
Figure 4-25: US - Kadcyla Quarterly Sales (US$ Million), 2022
Figure 4-26: Europe - Kadcyla Annual Sales (US$ Million), 2019 - 2023
Figure 4-27: Europe - Kadcyla Quarterly Sales (US$ Million), 2022
Figure 4-28: Japan - Kadcyla Annual Sales (US$ Million), 2019 - 2023
Figure 4-29: Japan - Kadcyla Quarterly Sales (US$ Million), 2022
Figure 4-30: US - Kadcyla per Unit and Price (US$) For 1 Powder Injection, May’2023
Figure 4-31: Kadcyla - Cost of Treatment for 100mg and 160mg of Intravenous Powder, May’2023
Figure 4-32: UK - Kadcyla Price per 180mg and 160mg Vial, May’2023
Figure 4-33: Kadcyla - Patent Expiration Year - US v/s UK
Figure 4-34: Global - Phesgo Annual Sales (US$ Million), 2020 - 2023
Figure 4-35: Global - Phesgo Quarterly Sales (US$ Million), 2022
Figure 4-36: US - Phesgo Annual Sales (US$ Million), 2019 - 2023
Figure 4-37: US - Phesgo Quarterly Sales (US$ Million), 2022
Figure 4-38: Europe - Phesgo Annual Sales (US$ Million), 2019 - 2023
Figure 4-39: Europe - Phesgo Quarterly Sales (US$ Million), 2022
Figure 4-40: US - Phesgo Price per Unit for 10mL of 20,000 Units Phesgo Subcutaneous Injection (US$), May’2023
Figure 4-41: US - Phesgo Price per Unit for 15mL of 30,000 Units Phesgo Subcutaneous Injection (US$), May’2023
Figure 4-42: Phesgo - Cost of Treatment Cycle (US$), May’2023
Figure 4-43: UK - Phesgo Price per Unit for 10mL of 600mg/600mg Phesgo Subcutaneous Injection, May’2023
Figure 4-44: UK - Phesgo Price per Unit for 15mL of 1200mg/600mg Phesgo Subcutaneous Injection, May’2023
Figure 4-45: Phesgo - Patent Approval and Expiration Year
Figure 4-46: Global - Trodelvy Annual Sales (US$ Million), 2021 - 2023
Figure 4-47: Global - Trodelvy Quarterly Sales (US$ Million), 2022
Figure 4-48: US - Trodelvy Annual Sales (US$ Million), 2021 -2023
Figure 4-49: US - Trodelvy Quarterly Sales (US$ Millions), 2022
Figure 4-50: Europe - Trodelvy Annual Sales (US$ Million), 2021 - 2023
Figure 4-51: Europe - Trodelvy Quarterly Sales (US$ Millions), 2022
Figure 4-52: Trodelvy - Per Unit and Price for 180mg of Intravenous Powder (US$), May’2023
Figure 4-53: Trodelvy - Cost of Treatment Cycle (US$), May’2023
Figure 4-54: UK - Trodelvy Price per 180mg Vial Powder, May’2023
Figure 4-55: Trodelvy - US v/s UK Patent Expiration Year
Figure 4-56: Global - Herceptin Annual Sales (US$ Million), 2019 - 2023
Figure 4-57: Global - Herceptin Quarterly Sales (US$ Million), 2022
Figure 4-58: US - Herceptin Annual Sales (US$ Millions), 2019 - 2023
Figure 4-59: US - Herceptin Quarterly Sales (US$ Million), 2022
Figure 4-60: Europe - Herceptin Annual Sales (US$ Million), 2019 - 2023
Figure 4-61: Europe - Herceptin Quarterly Sales (US$ Million), 2022
Figure 4-62: Japan - Herceptin Annual Sales (US$ Million), 2019 - 2023
Figure 4-63: Japan - Herceptin Quarterly Sales (US$ Million), 2022
Figure 4-64: US - Herceptin per Unit and Price for 150mg Intravenous Powder For Injection (US$)
Figure 4-65: Herceptin - Cost of Treatment (Schedule 1) (US$), May’2023
Figure 4-66: Herceptin - Cost of Treatment (Schedule 1) (US$), May’2023
Figure 4-67: Herceptin - Cost of Treatment for Metastatic HER2 Overexpressing Breast Cancer (US$), May’2023
Figure 4-68: UK - Herceptin Price per Vial for 150mg Powder, May’2023
Figure 4-69: Herceptin - Patent Filing Year v/s Expiration Year - US and Canada
Figure 4-70: Global - Enhertu Annual Sales (US$ Million), 2020 - 2023
Figure 4-71: Global - Enhertu Quarterly Sales (US$ Million), 2022
Figure 4-72: US - Enhertu Annual Sales (US$ Million), 2020 - 2023
Figure 4-73: US - Enhertu Quarterly Sales (US$ Million), 2022
Figure 4-74: EU - Enhertu Annual Sales (US$ Million), 2020 - 2023
Figure 4-75: EU - Enhertu Quarterly Sales (US$ Million), 2022
Figure 4-76: Japan - Enhertu Annual Sales (US$ Million), 2020 - 2023
Figure 4-77: Japan - Enhertu Quarterly Sales (US$ Million), 2022
Figure 4-78: US - Enhertu per Unit and Price for 100 mg Of Intravenous Powder (US$)
Figure 4-79: UK- Enhertu Price per 100mg Powder, May’2023
Figure 4-80: Enhertu - Cost of Treatment With 100mg intravenous Powder, May’2023
Figure 4-81: Margenza - Research and Development Annual Expense (US$ Million), 2020 - 2022
Figure 4-82: Margenza -Research and Development Quarterly Expense (US$ Million), 2022
Figure 4-83: US - Margenza Price per Unit for 25mg/mL Intravenous Solution (US$), May’2023
Figure 4-84: Margenza - Cost of Treatment with Different Volumes of Intravenous Solution, May’2023
Figure 4-85: Global - Tecentriq Annual Sales (US$ Million), 2019 - 2023
Figure 4-86: Global - Tecentriq Quarterly Sales (US$ Million), 2022
Figure 4-87: US - Tecentriq Annual Sales (US$ Million), 2019 - 2023
Figure 4-88: US - Tecentriq Quarterly Sales (US$ Million), 2022
Figure 4-89: Europe- Tecentriq Annual Sales (US$ Million), 2019 - 2023
Figure 4-90: Europe - Tecentriq Quarterly Sales (US$ Million), 2022
Figure 4-91: Japan - Tecentriq Annual Sales (US$ Million), 2019 - 2023
Figure 4-92: Japan - Tecentriq Quarterly Sales (US$ Million), 2022
Figure 4-93: US - Tecentriq Price per Unit for 840mg/14mL and 1200mg/20mL of Intravenous Solution (US$), May’2023
Figure 4-94: UK - Tecentriq Price per Unit for 840mg/14mL and 1200mg/20mL of Intravenous Solution, May’2023
Figure 4-95: Tecentriq - Global Patent Approval and Expiration Year
Figure 4-96: Global - Avastin Annual Sales (US$ Million), 2019 - 2023
Figure 4-97: Global - Avastin Quarterly Sales (US$ Million), 2022
Figure 4-98: US - Avastin Annual Sales (US$ Million), 2019 - 2023
Figure 4-99: US- Avastin Quarterly Sales (US$ Million), 2022
Figure 4-100: Europe - Avastin Annual Sales (US$ Million), 2019 - 2023
Figure 4-101: Europe - Avastin Quarterly Sales (US$ Million), 2022
Figure 4-102: Japan - Avastin Annual Sales (US$ Million), 2019 -2023
Figure 4-103: Japan - Avastin Quarterly Sales (US$ Million), 2022
Figure 4-104: US - Avastin Price per Unit for 25mg/mL of Intravenous Solution (US$), May’2023
Figure 4-105: UK - Avastin Price per Unit for Different Concentrations of Infusion Vial, May’2023
Figure 5-1: Global - Breast Cancer immunotherapy Drug Clinical Trials By Biomarker, 2023
Figure 5-2: Global - Breast Cancer immunotherapy Drug Clinical Trials By Company, 2023
Figure 5-3: Global - Breast Cancer immunotherapy Drug Clinical Trials By Country, 2023
Figure 5-4: Global - Breast Cancer immunotherapy Drug Clinical Trials By Patient Segment, 2023
Figure 5-5: Global - Breast Cancer immunotherapy Drug Clinical Trials By Phase, 2023
Figure 8-1: Available Monotherapeutic Approaches
Figure 8-2: Available Combinational Therapies
Figure 9-1: Emerging Immunotherapeutic Approaches Currently In Trial
Figure 10-1: Current Market Drivers
Figure 10-2: Current Market Challenges